Abstract

Hemoglobin vesicles (HbVs) are oxygen carriers consisting of Hb molecules and liposome in which human hemoglobin (Hb) molecules are encapsulated. Investigations of HbV biocompatibility have shown that HbVs have no significant effect on either the quality or quantity of blood components such as RBC, WBC, platelets, complements, or coagulation factors, reflecting its excellent biocompatibility. However, their effects on the immune system remain to be evaluated. HbVs might affect the function of macrophages because they accumulate in the reticuloendothelial system. Results show that splenic T cell proliferation is suppressed after injection of not only HbV but also empty liposome into rat, and show that macrophages that internalized liposomal particles are responsible for the suppression. However, the effect is transient. Antibody production is entirely unaffected. Further investigation revealed that those macrophages were similar to myeloid-derived suppressor cells (MDSCs) in terms of morphology, cell surface markers, and the immune-suppression mechanism. Considering that MDSCs appear in various pathological conditions, the appearance of MDSC-like cells might reflect the physiological immune system response against the substantial burden of liposomal microparticles. Therefore, despite the possible induction of immunosuppressive cells, HbVs are an acceptable and promising candidate for use as a blood substitute in a clinical setting.

Highlights

  • Hemoglobin (Hb) based-oxygen carriers can be roughly categorized into two types: Acellular modified Hb molecules and cellular liposome-encapsulated Hb

  • This means that more frequent transfusions of Hb vesicles (HbVs) are required to maintain blood Hb level high enough compared with red blood cell transfusion

  • The amount of IL-2 produced was no less than that produced in control splenocytes. These results suggest that concanavalin A (Con A) stimulation can fully activate T cells in the liposome-loaded splenocyte culture, but that they are unable to proliferate

Read more

Summary

Introduction

Hemoglobin (Hb) based-oxygen carriers can be roughly categorized into two types: Acellular modified Hb molecules and cellular liposome-encapsulated Hb. No marked change in the number of PMN, platelets, RBC, human hematopoietic stem/progenitor cells, activity of CH50, or coagulation time was observed after administration of HbVs into a rat or ex vivo experimental setting. The half-life of red blood cells is approximately 100 days in humans. Based on the half-life of HbV in cynomolgus monkeys (47–72 h) [8] that in humans is assumed to be shorter than 100 days This means that more frequent transfusions of HbV are required to maintain blood Hb level high enough compared with red blood cell transfusion. In order to mimic this clinical situation, the injection of a large amount of liposome or (HbV) solution into rats was principally conducted only once to evaluate its effect on immune function. We present a review of our data, and discusses possible effects of liposomal microparticles, including HbVs, on immune function

Effects of Liposomal Microparticles on T Cell Proliferation
Effects of HbVs on Antibody Production
11. Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call